NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed a UK distribution agreement for its SelectMDx prostate cancer test with Lab21.

Under the terms of the deal, Lab21 will serve as a non-exclusive distributor of the test in the UK, and send liquid biopsy samples to MDxHealth's clinical diagnostic lab in The Netherlands for analysis. Lab21 will reimburse MDxHealth for all testing services performed.

Additional terms were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Feb
27

In this webinar, Jill Viles, an Iowa mother with no clinical training, shares her story of how she self-diagnosed her rare condition, a muscle-wasting disease caused by a mutation in the LMNA gene. She will also discuss how she discovered that a mutation in the same gene is the underlying cause for the excess muscle phenotype exhibited by Canadian Olympic hurdler Priscilla Lopes-Schliep. 

Mar
13

This webinar will share how clinical genetics labs can integrate cytogenetics and molecular data to assess abnormalities using a single sample on a single workflow platform.

Apr
03

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research.